Olfr683, encoded by the Or56a5 gene, is a member of the olfactory receptor family in the house mouse (Mus musculus). As part of the G-protein-coupled receptor (GPCR) superfamily, Olfr683 is integral to olfaction, detecting odorant molecules in the nasal epithelium and initiating neuronal responses that lead to smell perception. These receptors, including Olfr683, are characterized by a 7-transmembrane domain structure, a feature common to many neurotransmitter and hormone receptors. They are responsible for recognizing odorants and initiating G protein-mediated signal transduction, typically involving the activation of downstream signaling pathways, often mediated by changes in intracellular messengers like cyclic AMP (cAMP). The complexity of GPCR signaling, including that of olfactory receptors like Olfr683, makes direct inhibition challenging. Hence, potential indirect inhibitors focus on modulating related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists, such as propranolol, atenolol, and metoprolol, reduce cellular cAMP levels, a key component in GPCR signaling. This reduction in cAMP may indirectly affect the signaling pathways of GPCRs, potentially influencing the function of olfactory receptors like Olfr683. Calcium channel blockers, including nifedipine and verapamil, alter intracellular calcium levels, another vital element in GPCR signaling. Changes in calcium dynamics can indirectly affect the function of GPCRs, including olfactory receptors.
Additionally, targeting other GPCR pathways, such as those modulated by angiotensin II receptors, provides another indirect approach to modulate olfactory receptor function. Antagonists like losartan and candesartan might alter the GPCR signaling environment, potentially affecting receptors like Olfr683. Alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine might also indirectly impact GPCR signaling mechanisms, including those of olfactory receptors. In summary, the indirect inhibition of Olfr683 involves an understanding of GPCR biology and the interconnected nature of cellular signaling pathways. The listed chemicals provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr683. While direct inhibition poses significant challenges, these indirect approaches offer potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, reduces cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways relevant to Olfr683. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, potentially indirectly influencing GPCR signaling pathways and impacting Olfr683 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr683. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and indirectly affecting Olfr683. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr683. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr683. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr683. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr683. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr683. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr683. | ||||||